# Alia Therapeutics S.R.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alia-therapeutics-s-r-l

- Industry: Biotechnology
- Headquarters: Milan, Italy
- Website: www.aliatherapeutics.com
- Total disclosed funding: $4.8M
- Latest round: Seed (Apr 17, 2023)
- Investors on record: 3

## About

Based in Milan, Italy, and founded in 2018, Alia Therapeutics S.R.L operates as a biotechnology company that develops therapeutic methods to treat chronic genetic diseases using gene editing technology. The company was founded by Anna Cereseto, Antonio Casini (CTO), and Gianluca Petris. In April 2023, Alia Therapeutics S.R.L. raised EUR 4.4 million in seed funding led by Sofinnova Partners and Indaco Bio.

The firm offers CRISPR technology and develops CRISPR-based medicines for genetic diseases. The solutions offered by the company include vesicles and lentiSLiCES. Vesicles is a traceless delivery of genome editing tools which is a production platform that allows getting an active genome editing product. Whereas lentislices deploy a self-limiting genome editing circuit into target cells which minimizes adverse effects.

The company plans to use the April 2023 funding to expand its business and develop its technology.

## Funding rounds

- Seed, Apr 17, 2023, $4.8M — Sofinnova Partners, Indaco Venture Partners
- Seed, Jun 30, 2021 — Sofinnova Partners, BiovelocITA S.r.l, Indaco Venture Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed
- BiovelocITA S.r.l — Seed
- Indaco Venture Partners (https://capitalatlas.ai/funds/indaco-venture-partners) — Seed